top of page

The purpose of the study is to evaluate the safety and effectiveness of an investigational drug named Lanifibranor to determine if it will help in the treatment of those who suffer from a non-cirrhotic liver disease called non-alcoholic steatohepatitis (NASH) fibrosis (stage2 or 3 indicating the amount of scarring).

You may be eligible to take part in the study if you:

  • Male or female ages18 years and older

  • Confirmed diagnosis of NASH and Stage F2/F3 of Liver Fibrosis

You may be compensated for time and travel, up to $3100 for your time and participation.

Contact us today to learn more about our current study opportunity. Signup online by completing the contact form below, or email our Patient Recruitment Specialist Haylee Kasuboski "". You can also call us toll free at 803.764.2406.

bottom of page